logo

Novocure (NVCR)



Trade NVCR now with
  Date
  Headline
8/16/2019 7:55:08 AM Can NovoCure Hit $100?
7/26/2019 8:36:26 AM Wedbush Is Cutting NovoCure (NVCR) FY20 Rev. Estimate To 484.6 M From 1601 M
7/26/2019 8:36:01 AM Wedbush Is Lowering NovoCure (NVCR) Q4 20 Rev. Estimate To 132.8 M From 1163 M
7/26/2019 8:35:49 AM Wedbush Is Lowering NovoCure (NVCR) Q3 20 Rev. Estimate To 124.8 M From 866.4 M
7/26/2019 8:35:24 AM Wedbush Is Cutting NovoCure (NVCR) Q2 20 Rev. Estimate To 118.8 M From 609.0 M
7/26/2019 8:35:11 AM Wedbush Is Lowering NovoCure (NVCR) Q1 20 Rev. Estimate To 108.2 M From 492.1 M
7/26/2019 8:34:51 AM Wedbush Is Increasing NovoCure (NVCR) FY19 Rev. Estimate To 351.1 M From 348.3 M
7/26/2019 8:34:40 AM Wedbush Is Cutting NovoCure (NVCR) Q4 19 Rev. Estimate To 99.9 M From 101.0 M
7/26/2019 8:34:29 AM Wedbush Is Lowering NovoCure (NVCR) Q3 19 Rev. Estimate To 91.2 M From 93.4 M
7/26/2019 8:34:04 AM Wedbush Is Cutting NovoCure (NVCR) FY20 Estimate To 0.63 From 8.09
7/26/2019 8:33:53 AM Wedbush Is Lowering NovoCure (NVCR) Q4 20 Estimate To 0.20 From 4.91
7/26/2019 8:33:41 AM Wedbush Is Lowering NovoCure (NVCR) Q3 20 Estimate To 0.17 From 2.95
7/26/2019 8:33:28 AM Wedbush Is Lowering NovoCure (NVCR) Q2 20 Estimate To 0.15 From 1.21
7/26/2019 8:33:16 AM Wedbush Is Cutting NovoCure (NVCR) Q1 20 Estimate To 0.10 From 0.63
7/26/2019 8:18:35 AM Wedbush Is Raising NovoCure (NVCR) FY19 Estimate To -0.09 From -0.19
7/26/2019 8:17:48 AM Wedbush Is Raising NovoCure (NVCR) Q4 19 Estimate To 0.04 From 0.02
7/26/2019 8:16:42 AM Wedbush Lowers NovoCure (NVCR) To Neutral From Outperform With $80 Up From $57 Price Target
5/24/2019 7:37:49 AM Wedbush Reiterates NovoCure (NVCR) At Outperform With $57 Price Target
3/22/2019 7:41:27 AM Novocure Begins INNOVATE-3 Trial In Recurrent Ovarian Cancer
3/21/2019 6:34:13 AM Eilon Kirson, Novocure’s Chief Science Officer And Head Of Research And Development To Retire, Effective May 1